Delineating the Role of βIV-Tubulins in Pancreatic Cancer: βIVb-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids  by Sharbeen, G. et al.
www.neoplasia.com
Volume 18 Number 12 December 2016 pp. 753–764 753
Address all
Research G
E-mail: p.p
1Thiswork
(NHMRC
Council Ne
Cancer Au
(J McCarro
NHMRC S
by the Aust
TechnologyDelineating the Role of βIV-Tubulins
in Pancreatic Cancer: βIVb-Tubulin
Inhibition Sensitizes Pancreatic
Cancer Cells to Vinca Alkaloids1,2correspondence to: Phoebe Phillips, PhD, Pancreatic Cancer Translational
roup, Lowy Cancer Research Centre, UNSW, Australia.
hillips@unsw.edu.au
was supportedby grants from theNationalHealth andMedical ResearchCouncil
; P A. Phillips, JMcCarroll,MKavallaris andDGoldstein; APP1024895), Cancer
w SouthWales (P A. Phillips, J McCarroll, M Kavallaris and DGoldstein), Cure
stralia Foundation Grant (P A. Phillips), Cancer Institute NSW Fellowship
ll, G Sharbeen), NHMRC CDF Fellowship (P A. Phillips, APP1024896), and
enior Research Fellowship (Maria Kavallaris, APP1058299). M Kavallaris is funded
ralian Research Council Centre of Excellence in Convergent Bio-Nano Science and
(project numberCE140100036) and anNHMRCProgramGrant (APP1091261).G. Sharbeen*,3, J. McCarroll†,‡, 3, J. Liu*,
J. Youkhana*, L.F. Limbri*, A.V.Biankin§,¶, A. Johns§,
M. Kavallaris†,‡, D. Goldstein* and P.A. Phillips*,‡
*Pancreatic Cancer Translational Research Group, Lowy Cancer
Research Centre, Prince of Wales Clinical School, University of
New South Wales (UNSW), Sydney, Australia, 2052; †Children's
Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney,
Australia, 2031; ‡Australian Centre for NanoMedicine, ARC
Centre of Excellence in Convergent Bio-Nano Science and
Technology, UNSW, Australia; §The Kinghorn Cancer Centre,
Cancer Program, Garvan Institute of Medical Research,
Darlinghurst, Sydney, Australia; ¶WolfsonWohl Cancer Research
Centre, Institute of Cancer Sciences, University of Glasgow,
Bearsden, Glasgow, Scotland G61 1BD, United KingdomAbstract
Pancreatic cancer (PC) is a lethal diseasewhich is characterizedbychemoresistance.Componentsof thecell cytoskeleton are
therapeutic targets incancer.βIV-tubulin isonesuchcomponent thathas two isotypes—βIVaandβIVb.βIVaandβIVb isotypes
only differ in two amino acids at their C-terminus. Studies have implicated βIVa-tubulin or βIVb-tubulin expression with
chemoresistance inprostate, breast, ovarianand lungcancer.However, nostudieshaveexamined the roleofβIV-tubulin inPC
or attempted to identify isotype specific roles in regulating cancer cell growth and chemosensitivity. We aimed to determine
the role of βIVa- or βIVb-tubulin on PC growth and chemosensitivity. PC cells (MiaPaCa-2, HPAF-II, AsPC1) were treated with
siRNA (control, βIVa-tubulin or βIVb-tubulin). The ability of PC cells to form colonies in the presence or absence of
chemotherapy was measured by clonogenic assays. Inhibition of βIVa-tubulin in PC cells had no effect chemosensitivity. In
contrast, inhibition of βIVb-tubulin in PC cells sensitized to vinca alkaloids (Vincristine, Vinorelbine and Vinblastine), whichwas
accompaniedby increasedapoptosis andenhancedcell cycle arrest.Weshow for the first time thatβIVb-tubulin, but notβIVa-
tubulin, plays a role in regulating vinca alkaloid chemosensitivity in PC cells. The results from this study suggest βIVb-tubulin
may be a novel therapeutic target and predictor of vinca alkaloid sensitivity for PC and warrants further investigation.
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Pancreatic ductal adenocarcinoma (PDA) is a deadly disease, with a
five-year survival rate of 6% [1]. It currently ranks as the fourth
leading cause of cancer-related deaths [1], and is predicted to become
the second leading cause of cancer death in the USA by 2030 due to alack of improvement in treatments [2]. Currently, the best known
treatments for PDA prolong survival by ~8 to 16 weeks [3,4]. The
difficulty in treating PDA stems from its propensity to acquire
chemoresistance and metastasize [5,6]. Thus, new therapeutic
approaches are needed to target these processes.Biospecimens were provided by the Australian Pancreatic Cancer Genome Initiative (APGI)
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microtubule network have been implicated in chemotherapy drug
resistance and aggressive disease in different tumor types [7,8]. The
microtubule network forms part of the cell cytoskeleton and consists of
cylindrical assemblies of α- and β-tubulin heterodimers [8,9].
Microtubules are essential for spindle formation during chromosome
alignment and segregation processes of mitosis [8,10,11]. Moreover,
they play a vital role in the trafficking of molecules within cells. Hence,
it is not surprising that microtubules have been subject to extensive
research as therapeutic targets for cancer [7].
There are seven distinct β-tubulin isotypes (βI, βII, βIII, βIVa,
βIVb, βV and βVI) that are expressed on different genes and have
differential tissue and cell specific expression [8,9]. These β-tubulin
isotypes share high amino acid sequence and structural homology and
can be distinguished by the last 15 to 20 amino acids of their highly
divergent carboxy terminal tail [8,9]. The importance of β-tubulin is
highlighted by the fact that tubulin-binding agents (TBAs) used in
the clinic (for example, taxanes and vinca alkaloids) bind to the
β-tubulin subunit and at high doses cause stabilization or
destabilization of microtubules leading to mitotic arrest and cell
death [7,8,11,12]. However, there are drawbacks with the use of
TBAs. Namely, they can be associated with side effects such as
peripheral neuropathy and neutropenia [11,13]. Cancer cells may also
acquire resistance to TBAs [7]. Interestingly, this can be associated
with altered expression of specific β-tubulin isotypes [8,14–18].
βIII-tubulin is the most extensively studied β-tubulin isotype in
relation to cancer, and its dysregulation has been associated with
increased chemoresistance and poor patient outcome in different
cancers (reviewed in [8]). Two studies reported that βIII-tubulin was
highly expressed in PDA tumors following surgical resection, but
absent in normal acinar and pancreatic islets [19,20]. Recently, our
laboratory demonstrated for the first time that silencing βIII-tubulin
expression in PDA cells significantly decreased their clonogenic
growth and increased chemosensitivity to broad classes of chemotherapy
drugs in vitro [20]. Furthermore, stable suppression of βIII-tubulin in
PDA cells using shRNA reduced tumor growth and metastases in an
orthotopic PDA mouse model [20].
Other β-tubulin isotypes have also been reported to be
differentially expressed in cancer cells and play a role in regulating
chemotherapy drug sensitivity. For example, βII-tubulin was shown
to be present at high levels in breast, lung and head and neck cancers
[21–23]. Moreover, the high βII-tubulin expression in head and neck
cancers correlated to a poor survival outcome. A functional role for
βII-tubulin in non-small cell lung cancer (NSCLC) cells was reported
by Gan et al. [24]. In this study the authors used RNA interference
(RNAi) to silence βII-tubulin expression in NSCLC cells in vitro.
This led to increased sensitivity to different types of vinca alkaloid
drugs. Interestingly, we showed that silencing βII-tubulin in PDA
cells had no effect on cell growth or chemosensitivity [20]. This
suggests that the β-tubulin isotypes may have unique and distinct
biological roles in different tumor types.
βIV-tubulin is another β-tubulin isotype which has been suggested
to be involved in regulating chemoresistance [16–18,24–26].
However, only limited studies have explored the role of
βIV-tubulin in cancer cells. There are two isotypes of this tubulin:
βIVa- and βIVb-tubulin, encoded by the TUBB4 and TUBB2C
genes, respectively. In health, βIVa-tubulin is predominantly
expressed in the brain, whereas βIVb-tubulin is expressed in the
testis, heart and skeletal muscle [27]. These two isotypes only differby 2 amino acids in their carboxy terminus [28,29]. βIVa-tubulin
levels have been reported to be up-regulated in several cancers
(ovarian, lung, prostate) [16,17,26] and its expression is increased in
taxol-resistant prostate and lung cancer cells. Recently, βIVa-tubulin
expression was shown to increase in NSCLC cells when exposed to
anchorage-independent growth conditions [30] and correlated with
resistance to paclitaxel [30]. βIVb-tubulin is also dysregulated in
cancer cells. Shalli et al. [18] reported increased expression of
βIVb-tubulin in docetaxel-resistant breast cancer cells when com-
pared to their respective docetaxel-sensitive parent cells. In another
study, Gan et al. [24] showed that silencing βIVb-tubulin (by siRNA)
in NSCLC cells did not change sensitivity to paclitaxel, but markedly
increased sensitivity to vinca alkaloids via increased apoptosis and cell
cycle arrest [24]. However, no functional role for either of the two
βIV-tubulin isotypes has been established in PDA. Furthermore,
there is little information describing the relative biological contribution
of each isotype within cancer cells. Using a gene-silencing approach we
specifically and potently silenced the expression of βIVa- and
βIVb-tubulin in PDA cells and determined their role in regulating
cell growth and chemotherapy drug sensitivity. Herein, we report for
the first time that βIVb-tubulin appears to be the major βIV-tubulin
isotype in PDA cells, and that silencing its expression in vitro:
1) decreases clonogenic anchorage-dependent cell growth and 2) increases
sensitivity to vinca alkaloids via an induction in apoptosis.
Materials and Methods
Immunohistochemistry
Human PDA tissue specimens were collected by surgical removal.
The use of human PDA tissue sections was approved by the UNSW
Human Research Ethics Committee (HCEC# HC14039).
Paraffin-embedded tissue sections were stained with βIV-tubulin
antibody (1:200) using methods as previously described [20]. 3,3′
diaminobenzidine (DAB) was used as the substrate and sections were
counterstained using hematoxylin. The specificity of the primary
antibodies was confirmed by including several negative controls: (a) omission
of the primary antibody and (b) incubationwith isotype control antibodies at
the same concentration as the primary antibodies.Culture and Maintenance of Pancreatic Cancer Cell Lines
PDA cell lines, MiaPaCa-2, HPAF-II and AsPC1 were obtained
from the American Type Culture Collection (ATCC). MiaPaCa-2 is
a PDA line derived from a primary PDA tumor, while HPAF-II and
AsPC1 are PDA lines derived from metastatic sites (HPAF-II and
AsPC1 derived from Ascites). All cell lines were validated using short
tandem repeat profiling (CellBank Australia). MiaPaCa-2 cells were
grown in Dulbecco's Modified Eagle Media (Gibco by Life
Technologies Pty Ltd., Mulgrave, VIC, Australia) supplemented
with 10% fetal bovine serum (FBS), 2.5% horse serum and 2 mM
L-glutamine. HPAF-II cells were grown in Minimal Essential Media
(Gibco by Life Technologies Pty Ltd., Mulgrave, VIC, Australia)
supplemented with 10% FBS, 2 mM L-glutamine and 1 mM sodium
pyruvate. AsPC1 cells were grown in Roswell Park Memorial
Institute-1640 medium (Gibco by Life Technologies Pty Ltd.,
Mulgrave, VIC, Australia) supplemented with 10% FBS and 2 mM
L-glutamine. All cancer cell lines were incubated at 37 °C
in humidified 5% CO2 atmosphere, and were lifted with 0.25%
trypsin/EDTA. Cells were routinely tested for mycoplasma and found
to be negative.
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Cancer cells were transfected using Lipofectamine® 2000 (Invitro-
gen by Life Technologies Pty Ltd., Mulgrave, VIC, Australia) with
ON-TARGETplus SMARTpool siRNAs targeting βIVb-tubulin,
βIVa-tubulin or non-silencing (ns-siRNA) (Millenium Science Pty
Ltd., Mulgrave, VIC, Australia). Transfection was performed with
100 nM siRNA at 24 hours post-seeding into a 6-well plate.
Real-Time Quantitative PCR (qPCR)
Total RNA from transfected cells was extracted using the Qiagen
RNeasy Plus kit (Qiagen Pty Ltd., Chadstone Centre, VIC, Australia)
according to the manufacturer's instructions and stored at −80 °C.
Concentration and purity of samples were determined with a
NanoDrop Spectrophotometer (Thermo Fisher Scientific, Scoresby,
VIC, Australia) by measuring the absorbance ratio at A260/280 and
A260/230. 500 ng of total extracted RNA was reverse transcribed
using a High Capacity cDNA Reverse Trancription kit (Applied
Biosystems by Life Technologies Pty Ltd., Mulgrave, VIC, Australia)
into cDNA, and real-time PCR was performed using the Quantitect
Power SYBR® Green PCR kit (Qiagen Pty Ltd., Chadstone Centre,
VIC, Australia) and ViiA™ 7 Real-Time PCR machine (Life
Technologies Pty Ltd., Mulgrave, VIC, Australia). The following
primer sequences were used: βIVa-tubulin primer (Cat. No.
L-009652-00-0020, Millennium Science Pty Ltd., Mulgrave, VIC,
Australia); βIVb-tubulin forward primer, 5′ AAAGAATTCGATG
CCACAGCCGAGGAGGA-3′, βIVb-tubulin reverse primer,
5′-AAATCTAGAATGAAAATGCTTTAATGG-3′. β2 microglob-
ulin (β2M) was used as housekeeping gene, and βIVa- and
βIVb-tubulin mRNA levels were normalized to β2M mRNA levels
as previously described by McCarroll et al. [20].
Western Blot
Whole cell lysates were prepared and western blot analysis was
performed as previously described [24,31,32]. Antibodies for
βIV-tubulin (Abcam cat. ab11315) and GAPDH were purchased
from Abcam Ltd. Protein bands were visualized using Amersham
Enhanced Chemiluminescent Substrate (ECL)Western Blot Detection
Reagent (GE Healthcare Australia Pty Ltd., Rydalmere, NSW,
Australia) and an ImageQuant LAS4000 luminometer (GEHealthcare,
Rydalmere, NSW, Australia).
Clonogenic Assays
Following transfection (24 h post-transfection), clonogenic assays
in the presence or absence of chemotherapy drugs were carried out as
previously described [20]. Briefly, cells were seeded into 6-well plates
(MiaPaCa-2 = 300cells/well; AsPC1/HPAF-II = 500 cells/well) and
incubated with drug 48 h post-transfection, for a total of 72 h.
Colonies (N50 cells) were counted after staining with crystal violet.
Immunofluorescence Staining
Immunofluorescence staining was performed as previously described
[20]. Chamber slides were incubated with the βIV-tubulin antibody
(1:500) at 4 °C overnight in a humidified chamber and then incubated
with an AlexaFluor-488 anti-mouse secondary antibody (1:1000,
Invitrogen) for 30 min. Alternatively slides were incubated with the
α-tubulin antibody (1:500; Sigma Cat. T9026) at 4 °C for 40 min, and
then incubated with an AlexaFluor-555 secondary antibody (1:1000)
for 30 min at room temperature. The slides were then mounted
using undiluted ProLong® Gold Antifade Reagent (Invitrogen)and sealed with a coverslip. Images were captured using a Leica SP5
confocal microscope.
Cell Cycle Assay
Cell cycle assays (48 h post-transfection) were performed as
previously described [20].
Apoptosis Assays
Annexin V Assay: PDA cells were treated (48 h post-transfection)
with fresh culture medium containing increasing amounts (0.1 nM,
0.3 nM, 0.5 nM) of vincristine for 24 h. Both adherent and floating
cells were collected and cell death was measured using the Annexin
V-PE/7-AAD-FITC reagent (Guava Nexin reagent, Millipore) as
previously described [20]. Samples were acquired on a Guava
EasyCyte HT System with InCyte software. Caspase 3/7 activity
assay: PDA cells were treated (48 h post-transfection) with fresh
culturemedium containing increasing amounts (0.1 nM, 0.3 nM, 0.5 nM)
of vincristine for 24 h. Caspase 3/7 activity in cell lysates was measured
using a luminescent plate reader as previously described [20].
Statistical Analyses
Data were expressed as mean ± SEM and analyzed using
GraphPad Prism 6 (GraphPad Software, Inc.). One-way ANOVA
(Dunnett's multiple comparison test) or paired t-test were used where
appropriate to measure statistical significance.
Results
βIV-Tubulin is Expressed in Human Pancreatic Ductal
Adenocarcinoma Cells
Currently, there are no antibodies that can distinguish between
βIVa- or βIVb-tubulin due to their high sequence homology, thus we
could only detect total βIV-tubulin protein. We first assessed whether
βIV-tubulin was present in human pancreatic tumor tissue. Total
βIV-tubulin was detected using immunohistochemistry in PDA
tissue collected after surgical resection. βIV-tubulin was highly
expressed in pancreatic tumor cells (Figure 1, A and B). In addition,
we measured βIV-tubulin expression in cell lysates collected from
three different PDA cell lines derived from primary (MiaPaCa-2) and
metastatic (AsPC1, HPAF-II) sites by Western blot. βIV-tubulin
levels were higher in all PDA cell lines (MiaPaCa-2, HPAF-II and
AsPC1) relative to normal human pancreatic ductal epithelial
(HPDE) cells (cells of origin of PDA; Figure 1C).
The Effect of Silencing βIVa- and βIVb-Tubulin Expression in
Pancreatic Cancer Cells
To establish if βIVa- or βIVb-tubulin could be silenced in PDA
cells, we transfected three independent PDA cell lines (MiaPaCa-2,
HPAF-II and AsPC1) with an siRNA pool (four siRNA sequences
that bind different regions of the transcript) targeting either
βIVa-tubulin, βIVb-tubulin or a non-silencing siRNA control
(ns-siRNA). RNA was harvested 72 h post-transfection and gene
silencing efficiency was evaluated by qPCR. βIVa-tubulin siRNA
treatment resulted in potent inhibition of βIVa-tubulin gene
expression in all PDA cell lines compared to ns-siRNA controls
(MiaPaCa-2: 98.5 ± 0.2% inhibition; HPAF-II: 71.3 ± 1.97%
inhibition; AsPC1: 88.3 ± 2.1% inhibition; Figure 2, A–C).
Likewise, treatment of cells with βIVb-tubulin siRNA resulted in a
potent reduction in βIVb-tubulin gene expression in all three cell
lines compared to ns-siRNA controls (MiaPaCa-2: 76 ± 4.6%
Figure 1. βIV-tubulin expression in PDA patient tissue and PDA cell
lines. A) Immunohistochemistry for βIV-tubulin in A) human PDA
tissue microarray specimens. B) Magnified field of human PDA
tissue stained for βIV-tubulin. Panels show tissue stained with
either isotype control antibody (i) or βIV-tubulin antibody (ii). The
isotype control was negative and tumor elements had strong
immunoreactivity for βIV-tubulin. C) Representative Western blot
(n = 3) for βIV-tubulin in protein extracts from pancreatic cancer
cell lines and human pancreatic ductal epithelial cells (HPDE).
GAPDH was used as a protein loading control.
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inhibition; Figure 2, D–F). Importantly, silencing βIVa-tubulin in all
PDA cells had no effect on βIVb-tubulin gene levels (Figure 2, A–C),
and silencing βIVb-tubulin had no effect on βIVa-tubulin gene
expression (Figure 2, D–F). These results demonstrated the high
specificity and activity of the siRNA for each gene and provided a
valuable tool to delineate the roles of βIVa-tubulin and βIVb-tubulin
in PDA cells. To determine the relative contribution of each isotype
to the total βIV-tubulin pool, protein was harvested from PDA cells
72 h post-transfection and total βIV-tubulin protein detected by
Western blot. Silencing βIVa-tubulin in our PDA cell lines resulted in
a negligible reduction in total βIV-tubulin protein (Figure 2, G–I). Incontrast, βIVb-tubulin siRNA markedly reduced total βIV-tubulin
protein expression in HPAF-II cells (Figure 2H) and completely
abolished total βIV-tubulin protein expression in MiaPaCa-2 and
AsPC1 cells (Figure 2, G–I). Taken together, these results suggest
that βIVb-tubulin comprised the majority of the βIV-tubulin pool in
PDA cells.
The Effect of Silencing βIVa- and βIVb-Tubulin on Pancreatic
Cancer Cell Clonogenic Growth and Chemosensitivity
Given the importance of β-tubulin isotypes in regulating growth
and chemotherapy drug sensitivity in cancer cells, we determined the
effect of silencing either βIVa- or βIVb-tubulin expression in PDA
cells on their clonogenic growth potential and chemosensitivity to a
structurally and functionally diverse range of drugs: Gemcitabine (an
anti-metabolite and first-line treatment for PDA), Paclitaxel (a
tubulin-stabilizing agent; albumin-bound paclitaxel is currently used
in combination with gemcitabine in the clinic) and Vincristine (a
tubulin-destabilizing agent). Silencing βIVa-tubulin alone had no
effect on the ability of any of the PDA cells to form cell colonies
(Figure 3, A–I). Furthermore, with the exception of paclitaxel in
AsPC1 cells (Figure 3F), βIVa-tubulin inhibition had no significant
effect on chemosensitivity in PDA cells (Figure 3, A–I). In contrast,
βIVb-tubulin knockdown alone reduced the ability of the
metastases-derived PDA cell lines HPAF-II (Figure 4, B, E and H)
and AsPC1 (Figure 4, C, F and I) to form cell colonies. These results
suggest that βIVb-tubulin may have a specific role in regulating PDA
cell growth. βIVb-tubulin knockdown also had a pronounced effect
on PDA chemosensitivity. βIVb-tubulin gene silencing increased the
sensitivity of HPAF-II cells to gemcitabine (Figure 4B) and paclitaxel
(Figure 4E). AsPC1 cells were also sensitized to paclitaxel following
knockdown of βIVb-tubulin (Figure 4F). Notably, silencing
βIVb-tubulin in all PDA cells resulted in increased sensitivity to the
vinca alkaloid vincristine compared to controls (Figure 4, G–I). Based
on these results, we focused on βIVb-tubulin for all further experiments.
Before continuing with our investigation of βIVb-tubulin in PDA
cells, we assessed the effect of silencing βIVb-tubulin expression in
non-tumorigenic human pancreatic duct epithelial (HPDE; Cells of
origin of PDA). We observed that βIVb-tubulin knockdown had no
effect on the proliferation of normal HPDE cells (Figure 5). Given
βIVb-tubulin knockdown was not toxic in HPDE cells, we did not
pursue any further functional analysis in these cells.
Given βIVb-tubulin knockdown sensitized all PDA cell lines to
vincristine, we next investigated whether βIVb-tubulin played a broader
role in regulating PDA cell sensitivity to vinca alkaloids. Clonogenic
assays were repeated usingMiaPaCa-2 andHPAF-II cells in the presence
of vinblastine or vinorelbine (both FDA approved vinca alkaloids).
βIVb-tubulin knockdown significantly sensitized both MiaPaCa-2 and
HPAF-II cells to vinblastine and vinorelbine (Figure 6, A–D). Our
results suggest that silencing βIVb-tubulin in PDA cells chemosensitizes
them to all major vinca alkaloids used in the clinic.
The Effect of Silencing βIVb-Tubulin in Pancreatic Cancer Cells
on Microtubule Structure and Cell Cycle
To determine if βIVb-tubulin knockdown disrupts the
microtubule network in PDA cells, we examined the effect of
silencing βIVb-tubulin in MiaPaCa-2 and HPAF-II cells on gross
microtubule structure by fluorescence confocal microscopy. Despite
potent knockdown of βIV-tubulin protein, no significant effects were
observed on themicrotubule structure, as shown by staining ofα-tubulin,
Figure 2. βIVa- and βIVb-tubulin silencing in pancreatic cancer cell lines. A-H) Real-time PCR analysis of βIVa- and βIVb-tubulin silencing in
MiaPaCa-2 (A and D), HPAF-II (B and E) and AsPC1 (C and F) cells. RNA was harvested from cells 72 h post-transfection with ns-siRNA,
βIVa-Tub siRNA or βIVb-tubulin siRNA. βIVa- and βIVb- tubulin mRNA levels were normalized to 18S mRNA. G-I) Western blot analysis of
βIVa- and βIVb- tubulin silencing in protein extracts from MiaPaCa-2 (G), HPAF-II (H) and ASPC1 (I) cells. Cell lysates were harvested from
cells 72 h after transfection with control siRNA (ns-siRNA), βIVa-tubulin siRNA (βIVa-Tub siRNA) or βIVb-tubulin siRNA (βIVb-Tub siRNA).
GAPDH was used as a loading control. Asterisks indicate significance (**P ≤ .01, ***P ≤ .001, ****P ≤ .0001; n ≥ 3).
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addition, no changes in the gene expression levels of total β-tubulin or the
closely related β-tubulin isotypes βI, βII or βIII-tubulin were observed in
cells treated with βIVb-tubulin siRNA (48 and 72 h post-transfection)
(Supplementary Figure 1, A–D). These results demonstrated that
there was no significant compensation in other β-tubulin genes when
βIVb-tubulin was inhibited.
We next examined whether the effects of βIVb-tubulin knock-
down on PDA clonogenic growth and chemosensitivity were induced
via a similar mechanism to TBAs. Treatment of cells with TBAs
results in an accumulation of cells in G2/M phase (preparation for cell
division/mitosis) of the cell cycle and a reduction of cells in G1 phase
(preparation for replication) and S phase (replication). We first
measured cell cycle distribution in PDA cells transfected with either
βIVb-tubulin siRNA or ns-siRNA, using propidium iodide staining
and flow cytometry. In contrast to TBAs, silencing βIVb-tubulin
alone in MiaPaCa-2 cells did not significantly alter their cell cycle
distribution relative to ns-siRNA controls (Figure 7, C and D). Given
we observed chemosensitization to vincristine, but not paclitaxel, in
all three lines, we repeated the experiment using MiaPaCa-2 cells in
the presence/absence of vincristine (tubulin destabilizer) andpaclitaxel (tubulin stabilizer). Consistent with their roles as tubulin
binding agents, both paclitaxel and vincristine caused cell cycle arrest
in mitosis (observed as an increase in G2/M phase cell population;
Figure 8). βIVb-tubulin knockdown had no effect on
paclitaxel-induced cell cycle changes, relative to ns-siRNA controls
(Figure 8A). However, βIVb-tubulin knockdown significantly
enhanced the arrest of cells in mitosis induced by vincristine
(observed as an additional increase in G2/M phase cell population;
Figure 8B).
βIVb-tubulin knockdown in pancreatic cancer cells induces
apoptosis in the presence of drug
Finally, we investigated whether βIVb-tubulin knockdown was
exerting its effects on chemosensitivity through the induction of
apoptosis. MiaPaCa-2 cells were transfected with βIVb-tubulin or
control siRNA (ns-siRNA) and treatments commenced 48 hours
post-transfection. Cells were cultured in the presence of increasing
concentrations of vincristine (0.1–0.5 nM) for a total of 24 h.
Apoptosis was examined by measuring caspase 3/7 activity and
Annexin V/7AAD staining and flow cytometry. PDA cells treated
with control (ns-siRNA) siRNA showed only a slight increase in
Figure 3. The effect of βIVa-tubulin silencing on pancreatic cancer cell clonogenic cell growth and chemosensitivity. Bars represent the
number of MiaPaCa-2, HAPF-II or AsPC1 cell colonies (mean + S.E.M. as a % of mock treatment) that formed from low density seeding
following transfection with control siRNA (ns-siRNA), or βIVa-tubulin siRNA (βIVa-Tub siRNA) and 72 h culture in titrations of Gemcitabine
(A-C), Taxol (D-F) or Vincristine (G-F). Asterisks indicate significance relative to the 0 nM control for the same siRNA. Hashes indicate
significance relative to the ns-siRNA control of the same drug dose (* or #P ≤ .05, **P ≤ .01, ***P ≤ .001, ****P ≤ .0001; n ≥ 4).
758 βIVb-Tubulin Regulates Pancreatic Cancer Growth and Chemosensitivity Sharbeen et al. Neoplasia Vol. 18, No. 12, 2016caspase 3/7 activity or annexin V/7ADD staining when treated with
highest concentration of vincristine (0.5 nM) (Figure 9, A and B). In
contrast, cells treated with βIVb-tubulin siRNA showed a small
increase in caspase 3/7 activity in the absence of drug (Figure 8A).
Addition of vincristine (0.3-0.5 nM) enhanced the increase in caspase 3/7
(Figure 9A). These results also correlated with a significant increase in
annexin V/7ADD staining (Figure 9B). These data indicate that the
chemosensitisation of PDA cells with suppressed βIVb-tubulin is
mediated via an induction of apoptosis.
Discussion and Conclusions
Dysregulated expression of β-tubulins in cancer cells is associated with
increased tumor aggressiveness and resistance to chemotherapy agents
in different cancers [7,8]. However, this is the first study to describe
the functional role of βIV-tubulin in pancreatic cancer cells.
Moreover, no study has attempted to delineate the individual roles
of βIVa-tubulin and βIVb-tubulin within the same cancer cell type.
Herein, we report for the first time novel roles for βIVb-tubulin in
regulating: (1) PDA cell anchorage-dependent growth; and (2)
sensitivity to chemotherapeutic drugs. Importantly, we demonstrate
that βIVb-tubulin has functionally distinct roles in PDA cells whencompared to βIVa-tubulin, and is a potential therapeutic target which
may sensitize PDA cells to vinca alkaloids.
A major limitation to understanding the functional role of
βIV-tubulin in cancer biology has been a lack of specific antibodies
and inhibitors to distinguish between the βIVa- and βIVb-tubulin
isotypes. To assess the role of both βIV-tubulins in PDA cells we used
an RNAi approach which was designed to silence either βIVa-tubulin
or βIVb-tubulin expression with high selectivity and specificity.
Knockdown of βIVa-tubulin using siRNA did not affect
βIVb-tubulin gene expression in PDA cells. Similarly, knockdown
of βIVb-tubulin had no effect on βIVa-tubulin gene expression.
These data demonstrated potent knockdown of each isotype at the
gene level, and confirmed that the siRNAs used in this study were
specific. We also showed that when βIVa-tubulin was silenced using
siRNA there was very little change in the protein expression of total
βIV-tubulin in PDA cells. In contrast, when βIVb-tubulin was
silenced using siRNA, total βIV-tubulin protein expression was
significantly decreased or in the case of AsPC1 and MiaPaCa-2 cells
completely abolished. This suggests that βIVb-tubulin is the major
isotype in the total βIV-tubulin pool in PDA cells. These results are in
accordance with a study [27] which measured the gene expression of
Figure 4. The effect of βIVb-tubulin silencing on pancreatic cancer cell clonogenic cell growth and chemosensitivity. Bars represent the
number of MiaPaCa-2, HPAF-II or AsPC1 cell colonies (mean + S.E.M. as a % of mock treatment) that formed from low density seeding
following transfection with control siRNA (ns-siRNA), or βIVb-tubulin siRNA (βIVb-Tub siRNA) and 72 h culture in titrations of Gemcitabine
(A-C), Paclitaxel (D-F) or Vincristine (G-F). Asterisks indicate significance relative to the 0 nM control for the same siRNA. Hashes indicate
significance relative to the ns-siRNA control of the same drug dose (* or #P ≤ .05, ** or ##P ≤ .01, *** or ###P ≤ .001, **** or
####P ≤ .0001; n ≥ 3).
Neoplasia Vol. 18, No. 12, 2016 βIVb-Tubulin Regulates Pancreatic Cancer Growth and Chemosensitivity Sharbeen et al. 759all seven β-tubulin isotypes in a panel of different tumor and
non-tumor cells. βIVb-tubulin was found to be expressed at high
levels in a large number of different tumor cells, while βIVa-tubulin
expression was low.Figure 5. The effect of βIVb-tubulin silencing on human pancreatic
ductal epithelial cell growth. Graph demonstrating that knockdown
of βIVb-tubulin in human pancreatic ductal epithelial (HPDE) cells
does not affect their proliferation (as % of mock transfection). Cells
transfectedwith control siRNA (ns-siRNA) served as controls; n = 3.Silencing βIVa-tubulin expression in PDA cells (primary and
metastases derived) had no effect on the clonogenic cell growth in the
absence of chemotherapy drugs. In addition, silencing βIVa-tubulin
expression in PDA cells, broadly speaking, had no effect on
chemosensitivity. The only exception to this was a small increase in
sensitivity to paclitaxel at one drug concentration in AsPC1 cells.
These results are not surprising given that βIVa-tubulin appears to
make up very little of the total βIV-tubulin pool in PDA cells. To
date, there are few reported studies examining βIV-tubulin in cancer
[16–18,24–26,33]. Only four studies have correlated increased
βIVa-tubulin expression with increased chemoresistance (to estra-
mustine and paclitaxel) in prostate, ovarian and lung cancer cells
[16,17,26,30]. This study is the first to explore the effect of silencing
βIVa-tubulin expression in any cancer.
Similarly, few studies have explored the role of βIVb-tubulin in
cancer cells [18,24,25,33]. Notably, we demonstrated that
βIVb-tubulin knockdown has significant effects on PDA cell growth
and chemosensitivity. For example, knockdown of βIVb-tubulin in
PDA cells significantly decreased clonogenicity in two out of three
PDA cells. These results are in contrast to Gan et al. [24] which
reported no effect on non-small cell lung cancer (NSCLC) cell growth
Figure 6. The effect of βIVb-tubulin silencing on pancreatic cancer cell chemosensitivity to vinblastine and vinorelbine. A-D) Bars
represent the number of MiaPaCa-2 (A-B) or HPAFII (C and D) cell colonies (mean + S.E.M. as a % of untreated control siRNA [ns-siRNA]
cells) that formed from low density seeding following transfection with ns-siRNA or βIVb-tubulin siRNA (βIVb-Tub siRNA) and 72 h culture
in titrations of vinorelbine or vinblastine. Asterisks indicate significance relative to the 0 nM control for the same siRNA. Hashes indicate
significance relative to the ns-siRNAcontrol of the samedrugdose (** or##P ≤ .01, *** or###P ≤ .001, ****or####P ≤ .0001; n = 3).
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Therefore, it is likely that the different β-tubulin isotypes play different
roles in different cell types. Interestingly, unlike TBAs, the decrease in
PDA cell growth following knockdown of βIVb-tubulin was not
associated with any changes in cell cycle progression. Studies examining
the mechanism of action for βIVb-tubulin regulation on PDA
tumorigenicity are currently under investigation in our laboratory.
βIVb-tubulin knockdown had marked effects on PDA cell
chemosensitivity. Firstly, silencing βIVb-tubulin expression increased
the sensitivity of HPAF-II cells to gemcitabine and paclitaxel. AsPC1
cells were also shown to have increased sensitivity to paclitaxel
following βIVb-tubulin knockdown, while no effect was observed in
MiaPaCa-2 cells. These cell-line specific effects indicate that
βIVb-tubulin may play a broad role in modulating chemoresistance
in specific subsets of PDA cells. In contrast, βIVb-tubulin
knockdown sensitized all PDA cell lines to vincristine. Further
investigation revealed increased sensitivity to other vinca alkaloids
such as vinblastine and vinorelbine following knockdown of
βIVb-tubulin. Both drugs are widely used to treat different solid
and hematologic tumors. Importantly, in the past vinca alkaloids have
been reported to have minimal activity against pancreatic cancer [34].
Our study provides new information on PDA cell resistance to vinca
alkaloids demonstrating that βIVb-tubulin plays an important
role in regulating sensitivity to these types of drugs. Together, these
data provide new opportunities to develop inhibitors against
βIVb-tubulin, or to select patients which express low levels of
βIV-tubulin which may allow for re-purposing of vinca alkaloids for
the treatment of PDA.
Importantly, silencing βIVb-tubulin in non-tumorigenic human
HPDE cells had no effect on their viability, suggesting that ourobserved anti-proliferative effects were specific to cancer cells. This is
in contrast to TBAs, which can arrest mitosis in any cell by stabilizing/
destabilizing all β-tubulin isotypes [8]. As a result, TBAs are
dose-limited by off-target toxicity, especially peripheral neuropathy
and neutropenia [35]. Despite this, TBAs are still effectively used in
the clinic and off-target toxicity is well managed [36]. For example,
vincristine has limited myelotoxicity but some neurotoxicity
associated with clinical sensory neuropathy, occasionally requiring
dose reduction but rarely cessation.
While βIVb-tubulin is also expressed in normal tissues (testis, heart
and skeletal muscle), it is unlikely that silencing a single β-tubulin
isotype in these cells would have the same off-target toxicity as
TBAs (which bind to all β-tubulin isotypes). In fact, the ability of
βIVb-tubulin inhibition to sensitize PDA cells to vinca alkaloids also
means that vinca alkaloid dosing could potentially be reduced in
combination with βIVb-tubulin inhibition. We have also made
significant advances in siRNA delivery technology [37], which not
only overcomes the lack of specific inhibitors against βIVb-tubulin,
but can also target therapy to PDA tumors. To highlight the
therapeutic potential of targeting a single β-tubulin isotype
up-regulated in PDA, we have previously administered therapeutic
doses of βIII-tubulin siRNA with nanoparticle which effectively
inhibited βIII-tubulin protein levels in orthotopic pancreatic tumors
without any off-target toxicity in other organs in mice [37].
A question that remains to be answered is how βIVb-tubulin exerts
its effect on PDA cell growth and chemosensitivity? It is established
that TBAs, which bind to all β-tubulins predominantly exert their
anti-cancer effect by inducing potent cell cycle arrest which coincides
with alterations to the structure of the microtubule network and
eventual cell death. Our data showed that knockdown of
Figure 7. The effect of βIVb-tubulin silencing on pancreatic cancer cell morphology and cell cycle. A and B) Confocal microscopy for
α-tubulin and βIV-tubulin in MiaPaCa-2 (A) and HPAF-II (B) cells transfected with control siRNA (ns-siRNA) (top panels) or βIVb-tubulin
siRNA (βIVb-Tub siRNA; bottom panels). Overlaid fluorescence images are shown in the far right panel of each row. C and D) Cell cycle
distribution was analyzed by propidium iodide staining and flow cytometry. Bars represent % of MiaPaCa-2 (C) or HPAFII (D) cells in
G0/G1-phase, S-phase, or G2/M-phase (mean ± S.E.M.); n = 3.
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it disrupt the cytoskeleton in PDA cells. However, βIVb-tubulin
knockdown in PDA cells enhanced vincristine-induced mitotic arrest,
but not paclitaxel-induced mitotic arrest. We also found that silencing
βIVb-tubulin in PDA cells also enhanced apoptosis induced by
vincristine treatment. Taken together, the results suggest that
βIVb-tubulin knockdown enhances the ability of vinca alkaloids to
arrest mitosis and consequently induce apoptosis.
As mentioned above, our most pronounced effects on PDA cell
chemosensitivity were observed in the presence of vinca alkaloids.
These class of drugs inhibit cell division by destabilizing microtubules.
Vinca alkaloid resistance in cancer cells is often associated with
overexpression of ABC drug efflux pumps P-glycoprotein and MRP1,
under the control of AKT signaling [38–41]. It is possible that
βIVb-tubulin may contribute to this signaling through its unique
C-terminus tail. β-tubulin isotypes differ in the last 15–20 amino acids
of their carboxy-terminal tail [27,42]. Importantly, this region is subject
to a diverse range of post-translational modifications [43,44]. These
modifications have the potential to influence vital protein–protein
interactions with the cell cytoskeleton/microtubule network [45,46].
For example, post-translational modifications have been identified for
βIII-tubulin in ovarian cancer cells when exposed to stress includinghypoxia and glucose-starvation [47,48]. These modifications allowed
βIII-tubulin to form direct protein–protein interactions with key
signaling proteins which are involved in promoting cell survival and
metastases. In support of this concept, a study by Miller et al. [25]
identified a novel post-translational modification in βIVb-tubulin in
liver tumors isolated from an orthotopic hepatic cancer mouse model.
The post-translational modification was increased during the growth
and development of liver cancer and was present in metastases in lungs
of mice. Therefore, it is possible that post-translational modifications in
βIVb-tubulin may allow for critical protein–protein interactions to
occur in PDA cells, which in turn, activate signaling pathways that
promote cell survival when the cells are exposed to chemical stress such
as chemotherapy drugs.
Another mode of action for βIVb-tubulin in regulating chemo-
sensitivity in PDA cells which should be considered is regulation of
microtubule dynamics in the presence of chemotherapy drugs. This
highly dynamic process involves the lengthening and shorting of
microtubules. This is most critical during cell division and TBAs
interfere with this process. For example, Gan et al. [32] demonstrated
that NSCLC cells with knockdown of βIII-tubulin had increased
suppression of microtubule dynamics when in the presence of low
concentrations of vincristine. This correlated to increased cell death.
Figure 8. The effect of βIVb-tubulin silencing on pancreatic cancer cell cycle in the presence of paclitaxel or vincristine. Cell cycle
distribution was analyzed by propidium iodide staining and flow cytometry. Bars represent % of MiaPaCa-2 cells in G1-phase, S-phase, or
G2/M-phase (mean + S.E.M.). 72 h post-transfection with either ns-siRNA or βIII-Tub siRNA cells were incubated for eight hours with (A)
paclitaxel or (B) vincristine. Asterisks indicate significance relative to the 0 nM control for the same siRNA. Hashes indicate significance
relative to the ns-siRNA control of the same drug dose (** or ##P ≤ .01, *** or ###P ≤ .001, **** or ####P ≤ .0001; n = 3).
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with βIVb-tubulin knockdown.
Collectively, this work provides valuable novel insight into the
functional roles of βIVa- and βIVb-tubulin in PDA cells.
βIVb-tubulin appears to be the major β-tubulin isotype making up
total βIV-tubulin in PDA cells, and plays an important role in
modulating PDA cell growth and sensitivity to vinca alkaloids. These
results provide a rationale for further investigation of sensitisation of
PDAs to this class of agents, in an in vivo setting.Figure 9. The effect of βIVb-tubulin silencing in pancreatic cancer cells
(ns-siRNA) or βIVb-tubulin siRNA (βIVb-Tub siRNA). 48 h later, cells we
Apoptosis was then measured using a caspase 3/7 activity assay (A)
indicate significance relative to the 0 nM control for the same siRNA.
same drug dose. Asterisks indicate significance (* or #P b .05, **PSupplementary data to this article can be found online at http://dx.doi.
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